X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16045) 16045
Newsletter (28) 28
Magazine Article (26) 26
Book Chapter (7) 7
Publication (4) 4
Book Review (3) 3
Web Resource (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10680) 10680
male (9682) 9682
animals (6617) 6617
piperazines - pharmacology (6330) 6330
piperazines - administration & dosage (5757) 5757
female (5676) 5676
piperazines - therapeutic use (5344) 5344
adult (3997) 3997
middle aged (3969) 3969
rats (3595) 3595
pharmacology & pharmacy (3485) 3485
imatinib mesylate (2925) 2925
piperazines - adverse effects (2692) 2692
aged (2576) 2576
dose-response relationship, drug (2427) 2427
sildenafil citrate (2417) 2417
benzamides (2376) 2376
treatment outcome (2314) 2314
mice (1988) 1988
oncology (1907) 1907
neurosciences (1889) 1889
psychiatry (1565) 1565
pyrimidines - administration & dosage (1555) 1555
pyrimidines - therapeutic use (1535) 1535
administration, oral (1401) 1401
time factors (1382) 1382
rats, sprague-dawley (1350) 1350
sildenafil (1324) 1324
piperazines - pharmacokinetics (1295) 1295
antineoplastic agents - therapeutic use (1167) 1167
purines (1094) 1094
sulfones (1091) 1091
hematology (1087) 1087
drug therapy (1082) 1082
adolescent (1072) 1072
double-blind method (1033) 1033
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1033) 1033
drug administration schedule (984) 984
imatinib (967) 967
research (962) 962
care and treatment (930) 930
rats, wistar (913) 913
analysis (908) 908
cancer (898) 898
antineoplastic agents - administration & dosage (897) 897
erectile dysfunction - drug therapy (861) 861
drug therapy, combination (857) 857
aripiprazole (844) 844
therapy (822) 822
efficacy (813) 813
pyrimidines - pharmacology (813) 813
double-blind (809) 809
disease models, animal (799) 799
medicine & public health (788) 788
serotonin (775) 775
drug interactions (762) 762
serotonin antagonists - pharmacology (756) 756
pyridines - pharmacology (752) 752
antipsychotic agents - therapeutic use (742) 742
erectile dysfunction (734) 734
young adult (711) 711
pyrimidines - adverse effects (704) 704
schizophrenia (693) 693
urology & nephrology (673) 673
cell line, tumor (654) 654
sulfones - therapeutic use (654) 654
cardiac & cardiovascular systems (653) 653
pharmacokinetics (649) 649
chronic myelogenous leukemia (647) 647
aged, 80 and over (644) 644
dosage and administration (636) 636
clinical neurology (632) 632
clinical trials as topic (623) 623
expression (617) 617
serotonin receptor agonists - pharmacology (615) 615
health aspects (609) 609
chronic myeloid-leukemia (607) 607
antipsychotic agents - adverse effects (600) 600
safety (595) 595
rat (589) 589
blood pressure - drug effects (585) 585
sulfones - administration & dosage (582) 582
protein kinase inhibitors - therapeutic use (580) 580
purines - therapeutic use (571) 571
abridged index medicus (570) 570
piperazines - chemistry (557) 557
schizophrenia - drug therapy (553) 553
phosphodiesterase inhibitors - therapeutic use (551) 551
apoptosis (549) 549
antipsychotic agents - administration & dosage (544) 544
inhibition (544) 544
piperazines - metabolism (543) 543
antineoplastic combined chemotherapy protocols - therapeutic use (538) 538
piperazines - blood (536) 536
pharmacology (535) 535
follow-up studies (534) 534
purines - administration & dosage (531) 531
drug synergism (526) 526
antineoplastic agents - pharmacology (525) 525
brain (521) 521
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15351) 15351
Japanese (303) 303
German (186) 186
Russian (153) 153
French (147) 147
Chinese (72) 72
Italian (58) 58
Spanish (43) 43
Portuguese (24) 24
Hungarian (23) 23
Polish (20) 20
Swedish (16) 16
Danish (14) 14
Norwegian (14) 14
Dutch (10) 10
Turkish (9) 9
Czech (4) 4
Bulgarian (2) 2
Hebrew (2) 2
Ukrainian (2) 2
Croatian (1) 1
Finnish (1) 1
Lithuanian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 0732-183X, 2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | FC-GAMMA-RIIIA | PROGRESSION-FREE SURVIVAL | MULTICENTER PHASE-II | SQUAMOUS-CELL CARCINOMA | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | SUNITINIB MALATE SU11248 | CHRONIC MYELOID-LEUKEMIA | IMATINIB PLASMA-LEVELS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PERIPHERAL VASCULAR DISEASE | PRASUGREL | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2155 - 2166
Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin... 
TRIALS | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | MULTICENTER | CLOPIDOGREL | TICAGRELOR | THROMBOSIS | RATIONALE | PREVENTION | ASPIRIN | CLINICAL-OUTCOMES | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Incidence | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Drug Administration Schedule | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Myocardial Ischemia - therapy | Aged | Hemorrhage - chemically induced | Aggregation | Treatment outcome | Care and treatment | Usage | Blood platelets | Analysis | Drug-eluting stents | Dosage and administration | Cardiovascular diseases | Thrombosis | Health aspects | Blood clot | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Drug delivery | Patients | Bleeding | Clinical outcomes | Cerebrovascular system | Coronary vessels | Implants | Clopidogrel | Drug therapy | Stents
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CYTOCHROME-P450 | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PRASUGREL | GASTROENTEROLOGY & HEPATOLOGY | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 11/2015, Volume 112, Issue 45, pp. 14084 - 14089
Marijuana exerts profound effects on human social behavior, but the neural substrates underlying such effects are unknown. Here we report that social contact... 
reward | endocannabinoid | oxytocin | ACTIVATION | HUMAN BRAIN | ANXIETY | social behavior | BEHAVIOR | MULTIDISCIPLINARY SCIENCES | MARIHUANA | SYNAPTIC PLASTICITY | NUCLEUS-ACCUMBENS | CANNABINOID RECEPTORS | MICE | anandamide | Endocannabinoids - metabolism | Immunohistochemistry | Piperazines - administration & dosage | Bornanes - administration & dosage | Clozapine - administration & dosage | Nucleus Accumbens - metabolism | Bornanes - pharmacology | Male | Carbamates - administration & dosage | Oxytocin - metabolism | Receptors, Cannabinoid - metabolism | Arachidonic Acids - metabolism | Benzamides - administration & dosage | Clozapine - pharmacology | Piperidines - pharmacology | Social Behavior | Benzamides - pharmacology | Carbamates - pharmacology | Pyrazoles - pharmacology | Piperidines - administration & dosage | Benzodiazepines - pharmacology | Mice, Inbred C57BL | Clozapine - analogs & derivatives | Polyunsaturated Alkamides - metabolism | Piperazines - pharmacology | Cocaine - administration & dosage | Cocaine - pharmacology | Pyrazoles - administration & dosage | Animals | Analysis of Variance | Benzodiazepines - administration & dosage | Signal Transduction - physiology | Mice | Lipids - analysis | Reward | Infusions, Intraventricular | Autism Spectrum Disorder - physiopathology | Influence | Cellular signal transduction | Research | Oxytocin | Analysis | Endocannabinoids | Biological Sciences
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 07/2009, Volume 157, Issue 5, pp. 831 - 843
Background and purpose:  Buprenorphine displays attributes of opioids, but also some features distinct from them. We examined spinal and supraspinal signal... 
mechanism of action | supraspinal | buprenorphine | analgesia (antinociception) | Supraspinal | Analgesia (antinociception) | Buprenorphine | Mechanism of action | OKADAIC-ACID | MU-OPIOID RECEPTOR | INTRINSIC EFFICACY | MOLECULAR-REARRANGEMENTS | SERINE/THREONINE PROTEIN PHOSPHATASES | PARTIAL AGONIST | ORL1 RECEPTOR | PHARMACOLOGY & PHARMACY | MORPHINE-THEBAINE GROUP | TAIL-FLICK TEST | INDUCED ANTINOCICEPTION | Fentanyl - administration & dosage | Piperazines - administration & dosage | Narcotic Antagonists - administration & dosage | Serotonin Antagonists - administration & dosage | Phosphoprotein Phosphatases - metabolism | Aminoquinolines - administration & dosage | Injections, Intraventricular | Oligonucleotides, Antisense - metabolism | Male | Opioid Peptides - administration & dosage | Pain - chemically induced | Adrenergic alpha-Antagonists - administration & dosage | Pain - metabolism | GTP-Binding Proteins - genetics | Okadaic Acid - administration & dosage | Brain - metabolism | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Benzamides - administration & dosage | Pain Threshold - drug effects | Anesthetics, Local - administration & dosage | Pertussis Toxin - administration & dosage | Receptor, Serotonin, 5-HT1A - metabolism | Disease Models, Animal | Receptors, Opioid - metabolism | Injections, Spinal | Pyridines - administration & dosage | Pain - prevention & control | Phosphoprotein Phosphatases - antagonists & inhibitors | Yohimbine - administration & dosage | Brain - drug effects | Buprenorphine - administration & dosage | Animals | Signal Transduction - drug effects | Analgesics, Opioid - administration & dosage | Acetylcholine | Mice | Naloxone - administration & dosage | Pain Measurement | Morphine - administration & dosage | Receptors, Opioid - drug effects | Serotonin 5-HT1 Receptor Antagonists | GTP-Binding Proteins - metabolism | Index Medicus | Research Papers
Journal Article
British journal of haematology, ISSN 0007-1048, 2015, Volume 168, Issue 1, pp. 69 - 81
Summary Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | MOLECULAR RESPONSES | DASATINIB | NILOTINIB | RESISTANT | INTERFERON-ALPHA | IN-VITRO | PATIENTS RECEIVING IMATINIB | INHIBITOR | HEMATOLOGY | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Haematological Malignancy
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 22, pp. 2100 - 2109
Journal Article